190 related articles for article (PubMed ID: 37563740)
1. Identification of cholesterol metabolism-related subtypes in nonfunctioning pituitary neuroendocrine tumors and analysis of immune infiltration.
Feng T; Hou P; Mu S; Fang Y; Li X; Li Z; Wang D; Chen L; Lu L; Lin K; Wang S
Lipids Health Dis; 2023 Aug; 22(1):127. PubMed ID: 37563740
[TBL] [Abstract][Full Text] [Related]
2. Identification of biomarkers associated with the invasion of nonfunctional pituitary neuroendocrine tumors based on the immune microenvironment.
Wu J; Guo J; Fang Q; Liu Y; Li C; Xie W; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1131693. PubMed ID: 37522128
[TBL] [Abstract][Full Text] [Related]
3. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Wen S; Li J; Yang J; Li B; Li N; Zhan X
Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
[TBL] [Abstract][Full Text] [Related]
5. PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion.
Tamura R; Ohara K; Morimoto Y; Kosugi K; Oishi Y; Sato M; Yoshida K; Toda M
Endocr Pathol; 2019 Jun; 30(2):81-89. PubMed ID: 30903445
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
7. Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
[TBL] [Abstract][Full Text] [Related]
8. Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors.
Portovedo S; Gaido N; de Almeida Nunes B; Nascimento AG; Rocha A; Magalhães M; Nascimento GC; Pires de Carvalho D; Soares P; Takiya C; Faria MDS; Miranda-Alves L
Mol Cell Endocrinol; 2019 Jun; 490():80-87. PubMed ID: 30999005
[TBL] [Abstract][Full Text] [Related]
9. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors.
Sato M; Tamura R; Tamura H; Mase T; Kosugi K; Morimoto Y; Yoshida K; Toda M
J Clin Med; 2019 May; 8(5):. PubMed ID: 31100921
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics.
Bao X; Wang G; Yu S; Sun J; He L; Zhao H; Ma Y; Wang F; Wang X; Wang R; Yu J
Theranostics; 2021; 11(1):132-146. PubMed ID: 33391466
[No Abstract] [Full Text] [Related]
12. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
[TBL] [Abstract][Full Text] [Related]
14. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
15. HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs.
Li B; Zhao S; Chen Y; Gao H; Xie W; Wang H; Zhao P; Li C; Zhang Y
Endocr Relat Cancer; 2024 Jun; 31(6):. PubMed ID: 38457246
[TBL] [Abstract][Full Text] [Related]
16. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
17. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
Kara M; Tokat F; Pamir MN; Danyeli AE
Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.
Rai A; Yelamanchi SD; Radotra BD; Gupta SK; Mukherjee KK; Tripathi M; Chhabra R; Ahuja CK; Kumar N; Pandey A; Korbonits M; Dutta P; Gaston-Massuet C
Acta Neuropathol Commun; 2022 Sep; 10(1):138. PubMed ID: 36114575
[TBL] [Abstract][Full Text] [Related]
19. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
Mangili F; Giardino E; Treppiedi D; Barbieri AM; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Mantovani G; Peverelli E
Neuroendocrinology; 2021; 111(6):568-579. PubMed ID: 32512568
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics.
Li J; Wen S; Li B; Li N; Zhan X
Cells; 2021 Aug; 10(9):. PubMed ID: 34571875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
